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chemotherapeutics are sometimes administered with drugs, like antiangiogenic compounds, to 
increase their effectiveness. Melatonin exerts antitumoral actions through antiangiogenic actions. 
We studied if melatonin regulates the response of HUVECs to chemotherapeutics (docetaxel and 
vinorelbine). The inhibition that these agents exert on some of the processes involved in angiogenesis, 
such as, cell proliferation, migratory capacity or vessel formation, was enhanced by melatonin. 
Regarding to estrogen biosynthesis, melatonin impeded the negative effect of vinorelbine, by 
decreasing the activity and expression of aromatase and sulfatase. Docetaxel and vinorelbine increased 
the expression of VEGF-A, VEGF-B, VEGF-C, VEGFR-1, VEGFR-3, ANG1 and/or ANG-2 and melatonin 
inhibited these actions. Besides, melatonin prevented the positive actions that docetaxel exerts on 
the expression of other factors related to angiogenesis like JAG1, ANPEP, IGF-1, CXCL6, AKT1, ERK1, 
ERK2, MMP14 and NOS3 and neutralized the stimulating actions of vinorelbine on the expression of 
FIGF, FGFR3, CXCL6, CCL2, ERK1, ERK2, AKT1, NOS3 and MMP14. In CAM assay melatonin inhibited 
new vascularization in combination with chemotherapeutics. Melatonin further enhanced the 
chemotherapeutics-induced inhibition of p-AKt and p-eRK and neutralized the chemotherapeutics-
caused stimulatory effect on HUVECs permeability by modifying the distribution of VE cadherin. Our 
results confirm that melatonin blocks proangiogenic and potentiates antiangiogenic effects induced by 
docetaxel and vinorelbine enhancing their antitumor effectiveness.
The development of new blood vessels is needed to provide oxygen and nutrients to the tumor cells and a way to 
escape from the primary site1. Angiogenesis is a main step in tumor growth and antiangiogenic agents are consid-
ered an interesting complementary strategy in cancer therapy2. Angiogenesis is a multi-step process: endothelial 
cell activation by growth factors, degradation of capillary wall by proteinases, formation of a branch point in 
the vessel wall, migration of endothelial cells and proliferation and reorganisation of endothelial cells to form 
tubules. In tumors, the interaction between endothelial cells and the microenvironment stimulates endothelial 
cells to proliferate, migrate and form a branching network of tubes3. A balance between angiogenic activating and 
inhibiting factors regulates the evolution of endothelial cells from a quiescent to a proangiogenic stage2. Among 
the principal proangiogenic factors are vascular endothelial growth factor (VEGF) and angiopoietins (ANG)4,5. 
Angiogenesis depends on the coordinated balance in time between the production of VEGF and angiopoietins6.
Melatonin, produced in the pineal gland, has antitumor effects in different cancer types, especially 
hormone-dependent tumors7–10. Melatonin oncostatic actions are exerted through different mechanisms, such 
as: indirect effects through a down-regulation of gonadal estrogens11; direct antiestrogenic actions at the tumor 
cell level12,13; induction of apoptosis14; antioxidant effects15; increase of the anticancer immunity16; reduction of 
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telomerase activity17,18; inhibition of fatty acid uptake and fat metabolic pathways19,20 and inhibition of angio-
genesis21–23. Concerning to its antiangiogenic effects, in MCF-7 cells melatonin reduces the expression of VEGF 
mRNA and inhibits proliferation, invasion, migration of endothelial cells and tubular network formation induced 
by VEGF22–24. Likewise, melatonin indirectly inhibits angiogenesis through the repression of IGF, EGF and ET-1 
(tumor growth factors and enhancers of tumor angiogenesis)25 and diminishing the production of ROS, which 
has an important function in stabilizing hypoxia-inducible factor HIF-α during hypoxia26.
Recently, different studies described that melatonin could have enhancing actions on the antineoplastic effects 
of chemotherapeutic agents27. Thus, the disruption of the nocturnal melatonin synthesis generates doxorubicin 
resistance and the administration of melatonin restores the sensitivity of tumor cells to doxorubicin and pro-
duces tumor regression28. Melatonin enhances the tunicamycin-induced apoptosis in breast cancer cells29 and 
sensitizes non-small-cell lung cancer cells to gefitinib30. In lung and cervical cancer cells melatonin stimulates 
cisplatin-induced cytotoxicity and apoptosis31,32. In addition, in a rat pancreatic tumor cell line, the administra-
tion of melatonin with 5-fluorouracil, cisplatin and doxorubicin potentiates chemotherapy-induced cytotoxicity 
and apoptosis33. Recently, our group described in a breast cancer cell line (MCF-7) that melatonin treatment 
increased the changes provoked by docetaxel on the levels of transcription of some genes (BAX, BAD, BCL2, 
TP53, CDKN1A, MUC1, GATA3, c-MYC and CDH13) and potentiated the actions on apoptosis34. Until now, all 
the studies about the influence of melatonin on the oncostatic actions induced by chemotherapeutic agents have 
been realized on tumor cells. Since it has been shown that in human breast cancer melatonin exerts antitumoral 
actions, some of which act by inhibiting the formation of new blood vessels, and it is also known the beneficial 
role of melatonin in combination with chemotherapeutics, we wanted in this work to analyze the role of mela-
tonin together with chemotherapy in the various stages of angiogenesis. For this, we used HUVECs treated with 
chemotherapeutics in the presence or not of melatonin in order to find out if the pineal hormone modifies the 
possible pro- or anti-angiogenic effects of these drugs. After treating human endothelial cells with docetaxel or 
vinorelbine, various experiments were carried out to check which levels of angiogenesis (cell viability, migration 
capacity, capillary formation, expression of factors that favor angiogenesis, etc.) were affected the joint treatment 
with melatonin, as well as, its effect on the transcription levels of some factors related to angiogenesis. To under-
stand through which mechanisms the indolamine works, in this study, we analyzed some cellular signaling path-
ways affected by other actions of the hormone. Finally, we studied if melatonin inhibitory effects of angiogenesis 
were reproducible in vivo, using the chorioallantoid membrane assay of chicken embryo.
Results
Actions of docetaxel and vinorelbine on endothelial cell proliferation and its modulation by 
melatonin. Firstly, we analysed the effects of docetaxel and vinorelbine and its regulation by melatonin in 
one of the first phases of angiogenesis such us proliferation of HUVECs. Melatonin at 1 mM alone had an anti-
proliferative action in HUVECs (Fig. 1). As expected, we observed that both doses (1 µM and 10 nM) of docetaxel 
and vinorelbine reduced HUVECs proliferation (p < 0.001) in a dose-dependent manner. Moreover, melatonin 
treatment before chemotherapeutics enhanced the antiproliferative effect exerted by docetaxel and vinorelbine at 
both concentrations (Fig. 1).
Actions of docetaxel and vinorelbine on endothelial cell motility and its modulation by mel-
atonin. Since endothelial cell migration is critical for the formation of new bloods during angiogenesis, we 
studied the consequences of adding melatonin treatment before docetaxel and vinorelbine on the HUVECs 
migration with the wound-healing assay. In this assay, we used docetaxel and vinorelbine at 10 nM because 
Figure 1. Melatonin increased docetaxel and vinorelbine-induced inhibition of cell proliferation in endothelial 
cells. Cell proliferation was measured by the MTT method. Data are expressed as the percentage of the control 
group (mean ± SEM). C control, M melatonin, D docetaxel and V vinorelbine. ap < 0.001 vs control; bp < 0.05 vs 
D 1 µM; cp < 0.001 vs D 10 nM; dp < 0.05 vs V 1 µM; ep < 0.001 vs V 10 nM.
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at 1 µM concentration cells did not migrate. As showed in Fig. 2 docetaxel and vinorelbine treatment for 10 h 
reduced significantly the distance migrated by HUVECs. Melatonin increased the inhibition on the migratory 
activity of HUVECs caused by docetaxel and vinorelbine and reduced the rate of wound closure approximately by 
50% of cells treated only with docetaxel or vinorelbine.
Actions of docetaxel and vinorelbine on endothelial cell capillary structure formation and its 
modulation by melatonin. Following the study of the different phases of angiogenesis, we investigated the 
capability of HUVECs to form capillary tubes on a matrigel matrix, the effects of docetaxel and vinorelbine in 
such process and its modulation by melatonin. As in the migration assay, we used docetaxel and vinorelbine at 
10 nM. HUVECs seeded on matrigel matrix formed tubular structures after 4 h (Fig. 3). Docetaxel and vinorel-
bine significantly (p < 0.001) inhibited capillary tube formation. Melatonin 1 mM treatment before docetaxel 
and vinorelbine reduced the formation of a meshwork of branching capillary-like tubes (Fig. 3) demonstrating a 
significant (p < 0.001) antivascular effect by enhancing the decrease of tubular structures formed and mesh area 
produced by both chemotherapeutic agents.
Actions of docetaxel and vinorelbine as selective estrogen enzyme modulators and its regula-
tion by melatonin. Since estrogens play a relevant role in the development and progression of mammary 
tumors with different effects on endothelium, we studied whether docetaxel and vinorelbine were able to modu-
late the transcriptional levels and later activity of the enzymes implicated in the estrogen synthesis in HUVECs 
and its modulation by melatonin. With this aim, we co-cultured HUVECs (lower compartment of the chamber) 
and MCF-7 (upper compartment of the chamber) cells, due to the fact that malignant cells stimulate the pro-
duction of estrogens in endothelial cells. Docetaxel did not produced any changes in the aromatase activity of 
endothelial cells whereas vinorelbine at 1 µM increased aromatase activity. Melatonin pretreatment counteracted 
this stimulatory effect (Fig. 4A).
With the aim of determining whether the stimulatory effect of vinorelbine on aromatase activity is due to the 
upregulation of Cyp19A1 mRNA expression, we perform qRT-PCR with specific primers for Cyp19A1. Cyp19A1 
mRNA expression was also significantly stimulated by 1 µM vinorelbine. Treatment with 1 mM melatonin in 
advance to chemotherapeutics addition reduced the expression of Cyp19A1 and was able to counteract the stim-
ulatory effect caused by vinorelbine (Fig. 4B).
Figure 2. Melatonin 1 mM (M) increased the inhibitory effect on endothelial cell migration induced 
by docetaxel 10 nM (D) and vinorelbine 10 nM (V). It was analysed through the wound healing assay. 
Representative photomicrographs of initial and after 5 and 10 h are shown at 10 x magnification and migration 
distance was measured as described in Material and Methods. Migrated area data shown are expressed as mean 
± SEM of four experiments. ap < 0.05 vs C (control); bp < 0.001 vs C; cp < 0.05 vs D; dp < 0.05 vs V.
4Scientific RepoRtS |         (2020) 10:4790  | https://doi.org/10.1038/s41598-020-61622-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
Since Cyp19A1 p I.7 is the main aromatase promoter involved in the regulation of Cyp19A1 expression in 
breast cancer, we studied by qRT-PCR its expression in endothelial cells. Melatonin decreased Cyp19A1 p I.7 
mRNA expression and counteracted the stimulatory effect induced by vinorelbine (Fig. 4C).
After that, we analysed whether melatonin could modulate the effects caused by docetaxel and vinorelbine on 
the activity and expression of sulfatase (STS), the enzyme that synthesizes estrone and 17β-estradiol from sulfated 
estrogens. Vinorelbine stimulated significantly the activity of this enzyme. Melatonin at 1 mM decreased STS 
activity in the presence or not of docetaxel and it was able to reduce the stimulatory effect induced by vinorelbine 
on STS activity (Fig. 5A).
We then wished to determine whether the modulatory effect of vinorelbine on STS activity is due to the reg-
ulation of the mRNA expression levels of STS. Vinorelbine significantly (p < 0.001) stimulated the expression of 
STS and the treatment with melatonin before chemotherapeutic significantly downregulated the expression of 
STS neutralizing the stimulatory effect induced by vinorelbine (Fig. 5B).
Then, we analysed the effects of docetaxel and vinorelbine on 17β-HSD1 activity and 17β-HSD1 transcription, 
the enzyme that converts estrone, androstenedione and 5-androstenedione into 17β-estradiol. We also studied 
whether or not melatonin could regulate these effects. Both docetaxel and vinorelbine reduced the activity of 
this enzyme. Melatonin also decreased the activity of 17β-HSD1 and significantly enhanced the inhibitory effect 
exerted by docetaxel and vinorelbine (Fig. 5C).
Docetaxel and vinorelbine downregulated the expression of 17β-HSD1 in HUVECs. Melatonin treatment 
before chemotherapeutics addition also downregulated the expression of 17β-HSD1 and enhanced the reduction 
caused by docetaxel and vinorelbine on 17β-HSD1 mRNA expression (Fig. 5D).
Regulation by melatonin of the docetaxel and vinorelbine-exerted changes on mRNA expres-
sion of the main pro-angiogenic factors, the VEGF gene family and angiopoietins. Docetaxel at 
1 µM induced a significant increase in the expression of VEGF-A, VEGFB, VEGF-C, VEGFR-1 and ANG-1 and the 
treatment with melatonin before chemotherapeutic caused a significant decrease of the expression of these angio-
genic factors neutralizing the stimulatory effect induced by docetaxel (Fig. 6). VEGF-A, VEGF-B, VEGF-C, VEGFR-
1, VEGFR-3 and ANG-2 mRNA expression was also upregulated by vinorelbine and melatonin pretreatment 
counteracted this stimulatory effect induced by vinorelbine (Fig. 6). Vinorelbine also downregulated VEGFR-2 and 
melatonin potentiated this inhibitory effect. Melatonin in combination with docetaxel and vinorelbine increased 
Tie2 mRNA expression, the angiopoietins cognate receptor (Fig. 6). Docetaxel and vinorelbine did not modify the 
expression of HIF-1α, however, melatonin decreased its expression with or without both chemotherapeutics.
Figure 3. Effects of melatonin 1 mM (M) on docetaxel 10 nM (D) and vinorelbine (V) 10 nM -induced changes 
on HUVEC capillary structure formation. Tubular structures were photographed and tubule area was measured 
as described in Material and Methods. Tubule area data are expressed as the percentage of the control group 
(mean ± SEM). ap < 0.001 vs C; bp < 0.001 vs D; cp < 0.001 vs V.
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Actions of docetaxel and vinorelbine on the expression of genes associated with angiogene-
sis and its modulation by melatonin. Since chemotherapeutics agents-induced modifications of gene 
expression associated with the angiogenic process are not well known, we employed the Human Angiogenesis 
RT2 Profiler PCR Array, which analyses the expression of 84 genes implicated in angiogenesis. Figure 7 shows the 
number of genes induced or repressed by the different treatments. Docetaxel enhanced the expression of 42 genes 
and decreased the expression of 7 genes. Vinorelbine induced the upregulation of 36 and the downregulation of 
22 genes. Melatonin alone downregulated 25 and upregulated 3 genes. Melatonin with docetaxel downregulated 
65 and upregulated 4 genes. In combination with vinorelbine, melatonin downregulated 40 and upregulated 30 
genes (Supplementary File with the expression changes of the 84 genes studied). Then, we selected for analysis 
by specific RT-qPCR those that had been modified under two or more treatments and we excluded those that we 
had analysed in the previous experiments (VEGF-A, VEGF-B, VEGF-C, VEGFR-1, VEGFR-2, VEGFR-3, HIF-1α, 
ANG-1, ANG-2, Tie2) and those whose modulation by melatonin has been previously reported. The effects on 
different angiogenic factors modified by docetaxel and vinorelbine with or without melatonin are shown in Fig. 8, 
grouped in three categories.
The first category compiles the angiogenic growth factors. Docetaxel enhanced the expression of FIGF, IGF-1 
and JAG1. Vinorelbine upregulated FGFR3 and FIGF expression and downregulated ANPEP. Melatonin neutral-
ized the stimulatory effect of docetaxel on the expression of JAG1, ANPEP and IGF-1 and also neutralized the 
stimulation of vinorelbine on the expression of FIGF and FGFR3 (Fig. 8A).
Secondly, extracellular matrix molecules related to angiogenesis. Docetaxel decreased LECT1 expression and 
increased MMP14 expression. Vinorelbine upregulated LECT1 and MMP14. Melatonin was able to counteract the 
Figure 4. Effects of melatonin 1 mM pretreatment on docetaxel and vinorelbine-induced changes on aromatase 
activity (A) and Cyp19A1 expression (B) and Cyp19A1 p 1.7 mRNA expression (C) in endothelial cells. Data 
are expressed as the percentage of the control group (mean ± SEM). C control, M melatonin, D docetaxel and V 
vinorelbine. ap < 0.01 vs C; bp < 0.05 vs D; cp < 0.001 vs V.
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actions of docetaxel and vinorelbine on the expression of MMP14. Likewise, melatonin neutralized the decrease 
induced by docetaxel by increasing LECT1 expression and increased TIMP3 expression in combination with 
vinorelbine (Fig. 8B).
Cytokines and other angiogenic factors belong to the third group. Both docetaxel and vinorelbine enhanced 
the expression of CXCL6, NOS3, CCL2, ERK1, ERK2 and AKT1. Melatonin neutralized the stimulatory effect 
of both docetaxel and vinorelbine on the expression of CXCL6, NOS3, ERK1, ERK2 and AKT1. Melatonin also 
counteracted the stimulatory action of vinorelbine on the expression of CCL2 (Fig. 8C).
Actions of docetaxel and vinorelbine on AKT and ERK signaling and its modulation by mela-
tonin. Total AKT and ERK protein expression was not affected by docetaxel and vinorelbine, but the contents 
of p-AKT and p-ERK were decreased in the presence of both chemotherapeutics. On the other hand, melatonin 
1 mM potentiated the inhibitory effect of docetaxel and vinorelbine on the phosphorylation levels of AKT and 
ERK (Fig. 9).
Actions of docetaxel and vinorelbine on vascular permeability and its modulation by mela-
tonin. With the objective of analysing if melatonin in combination with docetaxel or vinorelbine could affect 
vascular normalization, we addressed the effects of docetaxel and vinorelbine on endothelial cell permeability and 
its modulation by melatonin. Docetaxel and vinorelbine enhanced permeability of the HUVECs and melatonin 
was able to neutralize this effect (Fig. 10A).
VE-cadherin is one of the essential junctional molecule controlling the endothelial monolayer permeability, and 
since we have found that melatonin decreased cell permeability, we considered studying whether melatonin modified 
the distribution of VE-cadherin by immunostaining. In control endothelial cells, cell surfaces showed VE-cadherin 
staining. In contrast, docetaxel and vinorelbine disrupted this pattern and induced the internalization of the 
VE-cadherin and its disappearance from cell-to-cell contact. Melatonin reduced the internalization of the VE-cadherin 
induced by docetaxel and vinorelbine and enhanced VE-cadherin accumulation at cell surface (Fig. 10B).
In vivo actions of docetaxel and vinorelbine on the formation of new blood vessels and its mod-
ulation by melatonin. We assessed the formation of new vessels in the chick CAM assay. VEGF alone 
induced numerous blood vessels (Fig. 11A). The number of new formed vessels induced by VEGF was reduced 
by docetaxel treatment. In addition, melatonin treatment potentiated significantly (p < 0.001) the decrease of the 
number of vessel branch points produced by docetaxel and also decreased number of vessels in combination with 
vinorelbine (Fig. 11B).
Discussion
The formation of new vessels is essential in tumor ontogenesis and evolution. Inhibition of tumor angiogen-
esis has converted to an anticancer treatment in agreement with chemotherapy, radiotherapy or surgery35. 
Chemotherapeutic agents are sometimes administered with other drugs targeting different pathways that cause 
Figure 5. Effects of melatonin pretreatment on docetaxel and vinorelbine-induced changes on sulfatase (A) 
and 17β-HSD1 (C) activity and expression (B,D) in endothelial cells. Data are expressed as the percentage of the 
control group (mean ± SEM). C control, M melatonin, D docetaxel and V vinorelbine. ap < 0.01 vs C; bp < 0.05 
vs V; cp < 0.001 vs V; dp < 0.01 vs D.
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synergism and higher effectiveness of treatment. However, chemotherapeutic agents are frequently accompanied 
by deleterious side effects and development of drug resistance. Chemotherapeutic agents are classified according 
to their modes of action, as they act on different cellular targets affecting divers pathways which could cause cell 
cycle arrest and/or the induction of apoptosis. One of the most successful targeted therapy involves the microtu-
bule inhibitors, such as docetaxel, microtubule polymerizing agent, or vinorelbine, microtubule depolymerizing 
agent. They inhibit microtubule functions, which are required during cancer cell division36,37.
Combined with classical chemotherapeutic agents, melatonin enhances the efficacy of these drugs in breast 
cancer patients via a variety of mechanisms, including the capability of impairing angiogenesis21,22,27,34. Thus, in 
Figure 6. Effects of melatonin on docetaxel and vinorelbine-induced changes on mRNA expression of the main 
pro-angiogenic factors, VEGF-A, VEGF-B, VEGF-C, VEGFR1, VEGFR2, VEGFR3, ANG-1, ANG-2, Tie 2 and 
HIF-1α. Data are expressed as the percentage of the control group (mean ± SEM). C control, M melatonin, D 
docetaxel and V vinorelbine. ap < 0.001 vs C; bp < 0.001 vs D; cp < 0.001 vs V.
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the present study, we analysed the effects of docetaxel and vinorelbine at different stages of angiogenesis, compar-
ing the efficacy of the drugs alone or added together with the pineal hormone.
Here in, we tried to demonstrate that indeed melatonin both stimulates the antiangiogenic actions and abro-
gates any proangiogenic responses to docetaxel or vinorelbine. We have designed different experiments to assess 
different phases of the angiogenic response. First, we examined the cell division ratio of HUVECs. Docetaxel and 
vinorelbine, as expected, reduced endothelial cell proliferation. As we have already described in other works, mel-
atonin at 1 mM inhibited the proliferation of endothelial cells23. Besides, pretreatment with the pineal hormone 
further stimulates the inhibition of cell proliferation exerted by docetaxel and vinorelbine. This finding matches 
with previous results of our group: melatonin enhances apoptosis, further represses cell proliferation and is able to 
alter the modifications in gene expression triggered by docetaxel in the estrogen-responsive MCF-7 cell line34. The 
next stage of angiogenesis we tested was cellular migration. Docetaxel or vinorelbine reduced the migration capa-
bility of endothelial cells, in agreement with previously reports, describing that both vinorelbine and docetaxel 
inhibit endothelial cell motility and angiogenesis. In the case of docetaxel, by inhibiting the dynamic instability of 
Figure 7. Genes induced or repressed at least two-fold in endothelial cells treated either with docetaxel 1 µM 
or vinorelbine 1 µM and/or melatonin 1 mM for 4 h. Pathway-focused gene expression profiling was performed 
using a 96-well human breast cancer Human Angiogenesis RT2 Profiler PCR Array. Black columns indicate 
the percentage of upregulated genes and gray columns indicate the percentage of downregulated genes in each 
category.
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microtubules that possibly interact with G-proteins associated with focal adhesions and through the VE-cadherin 
mediated integrin β1/FAK/ROCK signalling pathway38–40.
In our study, the association of melatonin pretreatment with these chemotherapeutics agents further reduced 
by 50% the distance migrated by HUVECs in contrast to those groups treated only with docetaxel or vinorelbine. 
Once again melatonin enhanced docetaxel and vinorelbine effects, in this case on the migration of endothelial 
Figure 8. Effect of docetaxel 1 µM and vinorelbine 1 µM in the presence or not of melatonin 1 mM on the genes 
selected for analysis by specific RT-qPCR: (A) JAG1, IGF-1, FGFR3, ANPEP and FIGF as angiogenic growth 
factors, (B) TIMP3, MMP14 and LECT1 as extracellular matrix molecules, (C) CXCL6, NOS3, CCL2, ERK1, 
ERK2 and AKT1 as cytokines and other angiogenic factors. Data are expressed as the percentage of the control 
group (mean ± SEM). C control, M melatonin, D docetaxel and V vinorelbine. ap < 0.01 vs C; bp < 0.001 vs C; 
cp < 0.05 vs D; dp < 0.001 vs D; ep < 0.05 vs V; fp < 0.001 vs V.
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cells. Our results are in concordance with previous works describing that the inhibitory actions on angiogenesis 
exerted by melatonin on endothelial cells might take account by inhibition of cell migration23.
Since the development of tubes by endothelial cells is another important step in neo-angiogenesis, we studied 
the effect of docetaxel and vinorelbine, in the presence or not of melatonin, in an endothelial cell-vessel formation 
on matrigel matrix. Docetaxel and vinorelbine inhibit the three-dimensional configuration of our cell model into 
structures resembling capillary tubes41,42. In this study, we found that both docetaxel and vinorelbine decreased 
also the tubular network formation and melatonin disrupted tube assembly and markedly reduced the tubule area 
observed in response to both chemotherapeutics agents. In agreement, a previously published work indicates that 
the pineal hormone disrupts tube assembly, thwarts the arrangement of endothelial cells in a capillary network 
and dismantles those capillary networks assembled before treatment23.
It has been described how estradiol can accelerate the endothelial cell proliferation both in vitro and in vivo, 
promotes endothelial cell adhesion to a variety of matrix proteins and enhances cellular migration, ultimately 
leading to angiogenesis43. ERα transactivation seems to be one of the main mechanisms underlying vessel forma-
tion. In breast cancer, the action of estrogens, the expression of ER by endothelial cells correlates with angiogenic 
effects and the ability of the tumor to invade43. For this reason, we studied the effect of docetaxel and vinorelbine 
Figure 9. Effects of docetaxel 1 µM and vinorelbine 1 µM in the presence or not of melatonin 1 mM on AKT and 
ERK signaling pathways. Western blot representative images and analyses showing protein levels for AKT, ERK, 
p-AKT, p-ERK and GADPH as a control. Data are expressed as the percentage of the control group (mean ± SEM). 
C control, M melatonin, D docetaxel and V vinorelbine. ap < 0.01 vs C; bp < 0.001 vs D; cp < 0.01 vs V.
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on the transcription and activity of some enzymes (17β-HSD1, aromatase and estrogen sulfatase) participating 
in estrogen production in HUVECs. In our study, the greatest effects were obtained with vinorelbine, which 
induced an increase in aromatase and sulfatase transcription and enzymatic activity, whereas melatonin pretreat-
ment reverted this response. Vinorelbine increased also Cyp19A1 p I.7 expression, the main promoter driving 
aromatase transcription in endothelial cells in mammary tumors. Melatonin significantly downregulated the 
Cyp19A1 p I.7 and also counteracted the stimulatory effect induced by vinorelbine. Vinorelbine and docetaxel 
downregulated 17β-HSD1 transcription and inhibited its enzymatic activity. In this case, melatonin pretreat-
ment markedly reinforced this effect. Of note, melatonin neutralized the negative effect of vinorelbine, decreas-
ing aromatase and sulfatase activity and expression. At this moment, the effect of docetaxel and vinorelbine on 
the metabolism of estrogens in endothelial cells is not completely well established. It has been described that 
docetaxel decreases Cyp19A1 mRNA levels in mammary tumors, thus indicating that the anticancer actions of 
chemotherapy might account, at least partially, on its ability to suppress estrogens synthesis44.
Figure 10. Effects of melatonin on docetaxel 1 µM and vinorelbine 1 µM -induced changes on endothelial cell 
permeability (A) and VE-cadherin internalization (B). Arrows show VE-cadherin staining in cell to cell contact, 
in control and melatonin treated groups, and intracellular accumulation, in docetaxel and vinorelbine treated 
groups. Data are expressed as the percentage of the control group (mean ± SEM). C control, M melatonin, D 
docetaxel and V vinorelbine. ap < 0.05 vs C; bp < 0.01 vs D; cp < 0.01 vs V.
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VEGF is probably the most active signal protein directly stimulating the different stages of angiogenesis on 
endothelial cells45. Moreover, the ANG/Tie2 signalling complex is, together with VEGF, the other main molecular 
inductor of tumor angiogenesis5,46,47. Angiopoietins (ANG-1 and ANG-2) and VEGF act in a complementary and 
organized manner. Both angiopoietins can bind to the Tie2 receptor (belonging to the family of tyrosine kinases). 
ANG-1 promotes vascular maturation and stabilization. ANG-2 is an antagonist for the Tie2 receptor and causes 
vascular regression if VEGF is absent, whereas it stimulates angiogenesis when VEGF is present48,49. Docetaxel 
induced an increase in VEGF-A, VEGFB, VEGF-C, VEGFR-1 and ANG-1 transcription, whereas melatonin sig-
nificantly decreased these angiogenic factors neutralizing the stimulatory effect induced by docetaxel. At the same 
time, melatonin with docetaxel or vinorelbine upregulated Tie2 transcription in HUVECs. We know that the 
angiopoietins-Tie2 system has an autoregulation feedback system that modulates the overall activity of the Tie2 
system so that ANG-1, but not ANG-2 down-regulates Tie2 mRNA expression in endothelial cells50. The down-
regulation induced by melatonin on ANG-1 expression could explain the stimulatory effect of melatonin on Tie2 
expression. Vinorelbine upregulated VEGF-A, VEGF-B, VEGF-C, VEGFR-1, VEGFR-3 and ANG-2 transcription 
and the pineal hormone abolished this stimulatory effect induced by vinorelbine. Importantly, the induction of 
docetaxel and vinorelbine on VEGF-A, VEGF-B, VEGF-C, VEGFR-1, VEGFR-3, ANG-1 and ANG-2 expression 
should be regarded as a non-desirable side effect since they are increasing angiogenesis. To contrary, melatonin 
abolished this adverse effect and reduced their expression. In breast cancer, stimulatory effects in VEGF and 
ANG-1 after chemoendocrine therapy, such as doxorubicin, docetaxel, tamoxifen, exemestane or letrozol, have 
been described with low concentrations51. It has been already found that melatonin diminishes the levels of VEGF 
in several breast cancer cell lines and simultaneously triggers a decrease in the level of angiopoietins with a reduc-
tion of VEGF when endothelial and human breast cancer cells are cocultured22,23.
The same antiangiogenic properties of melatonin, mediated through a decline in the levels of VEGF has been 
described in several kind of tumors, such as neuroblastoma52, breast cancer22,23, ovarian53, gastric54, pancreatic55, 
prostate56 or hepatocarcinoma57. Additionally, the pineal hormone concomitantly administered with cyclophos-
phamide reduced VEGF-A transcription and tumor growth, both in salivary glands and Walker 256 carcinoma58.
We also addressed the transcription rate of 84 genes involved in angiogenesis in endothelial cells treated with 
docetaxel or vinorelbine in the presence or not of melatonin, in order to study whether chemotherapeutic agents 
modified some of these angiogenic factors and whether melatonin was able to counteract or to potentiate these 
effects. We further analyzed the expression of JAG1, ANPEP, FGFR3, IGF-1 and FIGF (growth factors promoting 
angiogenesis), TIMP3, MMP14 and LECT1 as extracellular matrix proteins and finally, a group of cytokines and 
other factors stimulators of angiogenesis, such as NOS3, CXCL6, ERK1, ERK2, CCL2 and AKT1. To study by 
Figure 11. In vivo effect of melatonin on the docetaxel or vinorelbine-induced changes on the VEGF-
stimulated angiogenesis in the chorioallantoic membrane assay. (A) Representative images of CAM. (B) Vessel 
number data shown are expressed as mean ± SEM. C control, M melatonin, VEGF vascular endothelial growth 
factor, D docetaxel and V vinorelbine. ap < 0.001 vs C; bp < 0.01 vs C; cp < 0.001 vs VEGF; dp < 0.001 vs VEGF 
D; ep < 0.001 vs VEGF V.
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specific RT-PCR we chose these genes, because they were altered in several experimental groups and, to date, it is 
not known whether melatonin is able to modulate them or not.
Concerning the regulatory actions on angiogenic factors, docetaxel upregulated FIGF, IGF-1 and JAG1 tran-
scription. Vinorelbine upregulated FGFR3 and FIGF expression and downregulated ANPEP. JAG1 is involved in 
cancer development at different levels, since it promotes tumor angiogenesis, stimulates malignant cell growth 
and triggers metastasis59. Transcription of JAG1 is elevated in mammary tumors and correlates with bad progno-
sis and low expectations of overall breast cancer survival59,60. In non-small cell lung cancer, in tumor-associated 
endothelial cells, high ANPEP levels are in association with angiogenesis and poor prognosis, as determined 
by microvessel density and/or VEGF expression61. IGF-I promotes tumor cell proliferation, malignant transfor-
mation, development of new vessels and tumor development62. FGFR3 high levels directly correlate with poor 
prognosis in mammary tumors63. Additionally, recent reports suggest that FGFR3 may participate in a molecular 
pathway leading to breast cancer development. This fact indicates that the FGFR3 protein might be a target to 
be considered in FGFR3-related breast cancer63. FIGF is related with tumor cell migration in colorectal cancer 
metastasis64. Here we describe that melatonin abolished the induction of transcription of JAG1, ANPEP and IGF-
1 mediated by docetaxel, and abolished the induction triggered by vinorelbine on the expression of FIGF and 
FGFR3. Chemotherapeutic agents upregulate angiogenic growth factors and melatonin, once again, neutralizes 
these undesirable effects.
Concerning the regulation of extracellular matrix proteins implicated in the angiogenic process, docetaxel 
decreased LECT1 expression and increased MMP14 expression. Vinorelbine upregulated LECT1 and MMP14. 
MMP14 is a metalloproteinase playing a crucial role promoting invasion and metastasis. This metalloproteinase 
cleaves proteins of the extracellular matrix and also of the basement membrane. As a result, growth factors, 
MMP-2 and MMP-13, are activated and cells can escape, migrating from the original tumor65. LECT1 inhibits 
the proliferation and tube morphogenesis of vascular endothelial cells in vitro as well as angiogenesis in the 
chick chorioallantoic membrane and impairs the VEGF-A-stimulated motility of endothelial cells by destabilizing 
lamellipodial extensions66. Our findings suggest that melatonin can abolish the stimulation exerted by docetaxel 
and vinorelbine on MMP14 expression and reverted the decrease of LECT1 expression consequence of docetaxel 
treatment. Melatonin, alone or in combination with vinorelbine, also increased TIMP3 expression, an inhibi-
tor of angiogenesis that limits vessel density close to tumors and reduces tumor growth67. Recently, it has been 
described that melatonin reduces Dalton’s lymphoma-induced angiogenesis by increasing TIMP3 expression68.
With respect to other factors implicated in angiogenesis, we found that both docetaxel and vinorelbine 
increased AKT1, ERK1, ERK2, CXCL6, NOS3 and CCL2 transcription. CXCL6 stimulates breast cancer devel-
opment triggering the phosphorylation of ERK1 and ERK2, thus inducing migration and growth of endothelial 
cells69. CCL2 turns human breast epithelial cells into a more aggressive and invasive phenotype70. NOS3 tran-
scription has been correlated with malignancy in human mammary cancer71. The protein kinases AKT1, ERK1 
and ERK2 participate in multitude of signaling transduction intracellular pathways. In the case of endothelial 
cells, these protein kinases activate a great number of proteins, which in turn stimulate cell division, cell survival, 
accelerate cell metabolism and induce vascular remodeling72. Melatonin annulled the activation in response to 
docetaxel and vinorelbine on CXCL6, NOS3, ERK1/2 and AKT1 transcription and abolished the stimulation of 
vinorelbine on CCL2 expression. In a cell-line model of hepatocellular carcinoma, the pineal hormone downreg-
ulated CXCL6 at high concentrations73. Recent reports link the reversion of drug resistance (in cancer chemo-
therapy treatments) by melatonin with its ability to inactive AKT and MAPK intracellular signal transduction 
pathways74. In our model, melatonin inhibited the transcription of AKT1 and ERK ½. Both vinorelbine and 
docetaxel prevent the activation of p-AKT and p-ERK and the pineal hormone enhanced this effect. In summary, 
our results point to melatonin and a molecule able to inhibit HUVEC cells proliferation, with antiangiogenic 
properties, effects likely mediated through AKT and ERK intracellular pathways, since it is well known the impli-
cation of these two kinases in different stages of angiogenesis: vascular endothelial cell growth, survival, prolifer-
ation and migration, ultimately leading to angiogenesis.
Recently, our group described that melatonin abolished the induction of HUVECs permeability in response 
to radiation. Cell permeability is crucial for vascular function. Therefore, we studied if docetaxel and vinorel-
bine could also influence permeability and the effects of melatonin in this process. Indeed, both chemother-
apeutics induced endothelial cell permeability; interestingly, the pineal hormone impaired their stimulatory 
effect. It is known that docetaxel75 and vinorelbine76 increases in permeability are accompanied by changes in 
vascular endothelial (VE)-cadherin. VE-cadherin belongs to the family of junction proteins and, in endothelial 
cells, participates in the regulation of vascular permeability77. VE_cadherin levels increase in cell to cell contact. 
Docetaxel and vinorelbine treatments result in intracellular accumulation of this adhesion protein. Melatonin 
reverted the action of chemotherapeutics decreasing the amount of intracellular VE-cadherin. Phosphorylation 
of VE-cadherin results in internalization of this adhesion molecule, and, as a consequence, the permeability of 
endothelial cells is increased77. This event is stimulated by VEGF, a permeability-increasing factor78. Once more, 
the inhibitory effect of the pineal hormone on VEGF levels by melatonin might be the explanation for the loss 
of cell permeability triggered by docetaxel and vinorelbine. Besides, the PI3K/AKT and MAPK/ERK signalling 
pathways are known to play a role in the increase of permeability exerted by VEGF in endothelial cells79. Thus, 
melatonin could regulate the cell permeability by decreasing the internalization of VE-cadherin, likely through a 
decrease of VEGF and blocking the phosphorylation of both ERK and AKT.
Additionally, we studied melatonin antiangiogenic activity in the CAM assay as a model of neovessel forma-
tion. According to the in vitro studies both docetaxel and vinorelbine diminished the vascular area and the pineal 
hormone intensified this effect. To our knowledge our results are the first ones demonstrating a inhibitory effect 
of the pineal hormone on angiogenesis when concomitantly administered with some chemotherapeutics in an 
in vivo model.
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Our results suggest that melatonin should be considered by its potential to improve the effects of conventional 
chemotherapeutic agents in breast cancer treatment. Most of our study has been performed in vitro. Further in 
vivo studies and clinical trials are necessary to clarify the efficacy of the association of melatonin with chemother-
apeutics, like docetaxel or vinorelbine.
In summary, melatonin showed inhibitory effects on angiogenesis in human endothelial cells in the presence 
of two chemotherapeutics, docetaxel and vinorelbine, by potentiating antiangiogenic actions and neutralizing 
proangiogenic actions induced by the chemotherapeutics agents. Chemotherapeutic agents inhibit tumor growth 
through different actions that reduce tumor angiogenesis. However, at the same time, they have actions that are 
proangiogenic, for example, vinorelbine increased aromatase activity, Cyp19A1 mRNA expression, Cyp19A1 p 
I.7 mRNA expression, sulfatase activity, STS mRNA expression, VEGF-A, VEGF-B, VEGF-C, VEGFR-1, VEGFR-3 
mRNA expression, ANG-2 mRNA expression, FGFR3, FIGF, MMP14, CXCL6, CCL2, AKT1 and NOS3 mRNA 
expression. Docetaxel increased VEGF-A, VEGFB, VEGF-C and VEGFR-1 mRNA expression, increased ANG-1 
mRNA expression, JAG1, FIGF, IGF-1, MMP14, CXCL6, AKT1, NOS3 mRNA expression and decreased LECT1 
transcriptional activity. Eventually, all these actions stimulate tumor growth. Melatonin treatment prevented all 
these deleterious effects of chemotherapeutic agents. Antiangiogenic effects of melatonin are likely accomplished 
through AKT and ERK inhibition since the pineal hormone diminished the phosphorylation levels induced by 
chemotherapeutics. Moreover, melatonin interferes with VEGF reducing angiogenesis by diminishing cell perme-
ability and modulating the internalization of VE-cadherin. Although it is known that melatonin reverts chemore-
sistance to chemotherapeutic agents in breast cancer treatment, the most valuable part of this work have been 
to find that docetaxel and vinorelbine have some non-desirable side effects that interfere with its effectiveness 
against cancer progression. Importantly, the pineal hormone neutralizes the negative actions of chemotherapeutic 
agents enhancing their antitumor action.
Materials and Methods
Cells and culture conditions. Human umbilical vein endothelial cells (HUVECs) were purchased from the 
American Tissue Culture Collection (Rockville, MD, USA). Based in previous works21,22, we cultured HUVECs 
as monolayer cultures in 58,1 cm2 culture plates in Vascular Cell Basal Medium (VCBM) (ATCC, Rockville, 
MD, USA) enriched with endothelial cell growth kit-BBE (ATCC, Rockville, MD, USA) which contains 2% fetal 
bovine serum (FBS), 0.2% Bovine Brain Extract, 5 ng/ml rhEGF, 10 mM Lglutamine, 0.75 units/ml heparin sul-
fate, 1 µg/ml hydrocortisone hemisuccinate, 50 µg/ml ascorbic acid, penicillin (20 units/ml) and streptomycin 
(20 µg/ml) (Sigma-Aldrich, Madrid, Spain) at 37 °C in a humid atmosphere with 5% CO2.
MCF-7 human breast cancer cells were also obtained from the American Tissue Culture Collection (Rockville, 
MD, USA). Based in previous works23, MCF-7 cells were cultured in 75 cm2 plastic culture flasks in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, Madrid, Spain) with 10% fetal bovine serum (FBS) (PAA 
Laboratories, Pasching, Austria), penicillin (20 units/ml) and streptomycin (20 μg/ml) (Sigma-Aldrich, Madrid, 
Spain) at 37 °C in a humid atmosphere with 5% CO2.
Since it is known that the presence of malignant epithelial cells in the culture enhances estrogen formation in 
endothelial cells we employed co-cultures of HUVECs and MCF7. As in previous works22, cells were co-cultured 
using Falcon 6-multiwell plates and Falcon cell culture inserts. HUVECs, which have been treated for a week with 
melatonin 1 mM or its diluent, were seeded (50 × 104 cells/well) on the bottom wells in VCBM enriched with 2% 
FBS and incubated overnight. Simultaneously, MCF-7 cells (40 × 104 cells), which have been treated for a week 
with melatonin 1 mM or its diluent, were cultured on the permeable membrane (0.45 µm) of the tissue-culture 
inserts in DMEM supplemented with 10% FBS. Both types of cells were cultured separately for 24 h to facilitate 
adhesion. Then, MCF-7 seeded inserts were moved over HUVECs cell cultures in the 6-well plates in fresh VCBM 
supplemented with 2% FBS to create the hanging co-culture setup. After 24 h, media were changed to VCBM with 
2% FBS or serum free, according to the experiment, containing docetaxel 1 µM or vinorelbine 1 µM or its diluent 
(ethanol at a final concentration lower than 0.001%) for 4 h to measure specific mRNA gene expression or for 0.5 
or 24 h to measure the different enzymatic activities.
Measurement of cellular proliferation. Because the reduction of tetrazolium salts is extensively accepted 
as a confident way to study cell viability and proliferation, we used the MTT [3(4,5dimethylthiazol-2-yl)-2,5-di-
phenyl tetrazolium bromide] assay80. MTT was obtained from Molecular Probes Inc. (Eugene, OR, USA). As in 
previous studies22, cells were cultured for one week in VCBM with 2% FBS and melatonin (1 mM) (Sigma-Aldrich, 
Madrid, Spain) or its diluent (ethanol at a final concentration lower than 0.001%). Then, both melatonin pre-
treated and control cells were cultured into 96-multiwell plates at a density of 8 × 103 cells/well, and incubated at 
37 °C for 24 h. Media were changed by fresh ones containing docetaxel (1 µM or 10 nM) (Sigma-Aldrich, Madrid, 
Spain), vinorelbine (1 µM or 10 nM) (Sigma-Aldrich, Madrid, Spain) and/or vehicle (ethanol at a final concentra-
tion lower than 0.001%). After 3 days, cell viability was measured reading absorbance at 570 nm in a microplate 
reader (Labsystems Multiskan RC 351, Vienna, VA, USA).
Measurement of cellular aromatase activity. We analyzed aromatase activity in endothelial cells by the 
tritiated water release assay, according to the previously described81. HUVECs and MCF-7 cells, which have been 
treated for a week with melatonin 1 mM or its diluent, were cocultured together as indicated previously. Based in 
previous works21, after an homogenous monolayer of preconfluent HUVECs was reached, media were aspirated 
and changed to serum-free media with the labeled substrate 300 nM [1β-3H(N)]-androst-4-ene-3,17-dione (NEN 
Life Science Products, Boston, MA, USA) (75–80 Ci/nM) in the presence of docetaxel 1 µM or vinorelbine 1 µM 
or the diluent (ethanol). Twenty four hours later, flasks were put on ice for 15 min and media were shifted to tubes 
with 0.25 ml ice-cold 30% tricholoroacetic acid (w/v), vortexed and centrifuged at 1700 g for 15 min at 4 °C. The 
supernatants were extracted with chloroform, vortexed and centrifuged at 1700 g for 15 min at 4 °C. The resulting 
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aqueous supernatants were adsorbed with 5% dextran-coated charcoal (Sigma-Aldrich, Madrid, Spain), vortexed, 
centrifuged at 1700 g for 15 min at 4 °C and the supernatants were added to vials with scintillation cocktail and 
counted in a beta counter (Beckman LS 6000 IC, Fulleton, CA, USA). Incubating dishes containing medium with 
the tritiated androgen, but no cells, we obtained the blank values which were substracted from each sample. The 
values were also corrected by taking into account the fractional retention of tritium in medium water throughout 
the processing, which was always higher than 85%.
Measurement of steroid sulfatase (STS) activity. STS activity in endothelial cells was studied by the 
formation of estrone from a labelled substrate ([6,7-3H(N)]-estrone sulfate ammonium salt)82. HUVECs and 
MCF-7 cells, which have been treated for a week with melatonin 1 mM or its diluent, were cocultured together as 
indicated previously. As we previously described83, when a homogenous monolayer of preconfluent HUVECs was 
reached, media were changed by fresh ones containing 20 nM [6,7-3H(N)]-estrone sulfate ammonium salt (NEN 
Life Science Products, Boston, MA, USA) (57.3 Ci/mM) in the presence of either docetaxel 1 µM or vinorelbine 
1 µM or its diluent (ethanol at a final concentration lower than 0.001%). After 24 h, culture dishes were put on ice 
for 15 min and 1 ml of the media was placed in tubes containing 5 ml of toluene, vortexed 90 s and centrifuged at 
1000 xg for 15 min at 4 °C. The resulting organic phase was added to vials with scintillation cocktail and counted 
in a beta counter. The amount of radioactivity measured in the [3H]-toluene was corrected by subtracting the 
blank values from each sample and by taking into account the fractional retention of tritium in medium water 
through assay, which was higher than 95%.
Measurement of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) activity. The activity 
of 17β-HSD1 was studied in endothelial cells by the formation of estradiol from a labelled substrate [2,4,6,7-3H(N
)]-estrone84. HUVECs and MCF-7 cells, which have been treated for a week with melatonin 1 mM or its dil-
uent, were cocultured together as indicated previously. When we get a homogenous monolayer of preconflu-
ent HUVECs, media were replaced for fresh ones including 2 nM [2,4,6,7-3H(N)]-estrone (NEN Life Science 
Products, Boston, MA, USA) (100 Ci/mM) in the presence of either docetaxel 1 µM or vinorelbine 1 µM or its 
diluent (ethanol at a final concentration lower than 0.001%) and incubated 30 min. After incubation, media were 
processed as we previously described83, they were transferred to tubes containing 2 ml of diethyl ether, vortexed 
and centrifuged at 800xg for 5 min at room temperature. The aqueous phase was frozen and the resulting organic 
phase was decanted, evaporated in tubes with 40 µl of estradiol 10 mM. The residue was resuspended in diethyl 
ether and separated by TLC using dichloromethane/ethyl acetate (4:1; v/v). Once the spots had been visualised, 
excised and eluted with methanol, they were counted in a liquid scintillation counter. Values were corrected for 
blanks and tritium recovery, which was higher than 85%.
Human angiogenesis Rt2 profiler PCR array. Pathway-focused gene expression profiling was per-
formed using a 96-well Human Angiogenesis RT2 Profiler PCR Array (Qiagen, USA). In this array, each well con-
tains all the components required and designed to generate single, gene-specific amplicons, testing the expression 
of 84 genes related to angiogenesis (growth factors and receptors, adhesion molecules, proteases, inhibitors and 
other matrix proteins, transcription factors, cytokines and chemokines), plus 5 housekeeping genes. Each RT2 
Profiler PCR array plate also includes controls for data normalization, genomic DNA contamination detection, 
RNA sample quality and general PCR performance. As in previous works34, HUVECs, which have been treated 
for a week with melatonin 1 mM, were cultured into 60 × 15 mm plates in VCBM supplemented with 2% FBS and 
incubated at 37 °C for 24 h to allow for cell attachment. Then media were replaced by fresh ones with 2% FBS and 
containing either docetaxel (1 µM) or vinorelbine (1 µM) alone or in combination with 1 mM melatonin and/or 
vehicle (ethanol at a final concentration lower than 0.0001%). After 4 h of incubation, total RNA was extracted 
and reverse transcribed. The cDNA template was mixed with the appropriate amount of RT2 SYBR Green qPCR 
Mastermix (Qiagen GmbH, Germany), aliquoted 25 µl to each well of the same plate, and then the real-time PCR 
cycling program was performed in an MX3005P (Agilent, CA, USA) following the manufacturer’s instructions. 
Amplification was initiated by 1 cycle at 95 °C for 10 min and then performed for 40 cycles for quantitative anal-
ysis using the following temperature profile: 95 °C for 30 sec (denaturation); 60 °C for 60 sec (annealing/exten-
sion). Dissociation curves were performed to verify that only a single product was amplified. The Ct data for 
each gene were analyzed using the Qiagen RT2 profiler PCR array data analysis software. Data are represented as 
fold-regulation between the experimental groups and the control cells. Fold-change values less than one indicate 
a negative or downregulation, and the fold-regulation is the negative inverse of the fold-change.
Measurement of specific mRNA gene expression. Measurement of different mRNA genes expres-
sion in endothelial cells were performed by qRT-PCR after incubation of cells, which have been treated for a 
week with melatonin 1 mM, with either docetaxel 1 µM or vinorelbine 1 µM or its diluent (ethanol at a final 
concentration lower than 0.001%) for 4 h. The total cellular RNA was isolated from HUVECs and purified with 
the Nucleospin RNA II Kit (Machenery-Nagel, Düren, Germany) following the manufacturer’s instructions. As 
we previously described83, integrity of RNA was evaluated by electrophoresis in ethidium bromide-stained 1% 
agarose-Tris-borate EDTA gels. The absorbance ratio A260 nm/A280 nm was> 1.8. For cDNA synthesis 1 µg of total 
RNA was denatured at 65 °C for 10 min and reverse transcribed for 50 min at 45 °C with cDNA Synthesis kit 
(Bioline, London, UK) in a final volume of 20 μl in the presence of 500 ng of oligo (dT) 12–18 primers. The 
primers used for amplification (Sigma Genosys Ltd., Cambridge, UK) are listed in Table 1. As a control quanti-
fication, s14 mRNA was also subjected to real-time RT-PCR using a set of specific primers (Sigma Genosys Ltd., 
Cambridge, UK). RT-PCRs were performed in a MX3005P system (Stratagene, La Jolla, CA, USA) using Brilliant 
SYBR Green PCR Master Mix (Applied Biosystems, Madrid, Spain) following the manufacturer’s instructions. 
Amplifications were performed for 40 cycles using the following temperature profile: 60 °C, 45 sec (annealing); 
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72 °C, 30 sec (extension) and 95 °C, 30 sec (denaturation). Each reaction was run ninefold by quadruplicate. 
Melting curves were performed to verify that only a single product with no primer-dimers was amplified. For the 
primers used there were no differences between transcription efficiencies, and the fold-change in each sample 
was calculated by the 2−∆∆Ct method85. The fractional cycle at which the amount of amplified targets becomes 
significant (Ct) was automatically calculated by the PCR program.
Endothelial cell migration assay: wound healing assay. HUVEC control or melatonin 1 mM, treated 
for a week, cells were cultured into 6-well plates (Falcon) in VCBM enriched with 2% FBS and were allowed to 
reach full confluence. Based in previous works23, a line of cells was scraped away in each plate using a pipette tip. 
Cells were washed with PBS and docetaxel 10 nM or vinorelbine 10 nM or its diluent (ethanol at a final concen-
tration lower than 0.001%) was added to each plate. After that, four randomly selected views along the scraped 
line in each plate were photographed using an ORCA R2 camera (Hamamatsu Photonics, Massy Cedex, France) 
attached to a microscope set Nikon Ti (Werfen Group, Barcelona, Spain) at 10x magnification. Photomicrographs 
were taken every 10 minutes until the wound was completely filled in controls (after 10 hours). Initial and final 
wound sizes were determined using the Nis Elements v.3.8 software (Nikon, Tokyo, Japan) and the difference 
between the two was used to determine migration distance using the following formula: initial wound size minus 
final wound size divided by two.
Endothelial cell differentiation assay: endothelial cell capillary-like tube formation assay. To 
study HUVECs tube formation we used the In vitro Angiogenesis Assay Tube Formation Kit (Cultrex, Trevigen 
Inc, Gaithersburg, MD, USA) following the manufacturer’s instructions. As we previously described24, growth 
factor-reduced Basement Membrane Extract (BME) was added into a 24-well plate and polymerized for 1 h at 
37 °C. After that, cells (3 × 105 per well), treated or not with melatonin 1 mM for a week, were cultivated in VCBM 
with 2% FBS in the presence of either docetaxel 10 nM or vinorelbine 10 nM or its diluent (ethanol at a final 
concentration lower than 0.001%). After 4 h, 5 random fields were selected per well and tubular structures were 
photographed with a camera Nikon Sight DS-SML1 (Sendai Nikon Corporation, Miyagi, Japan) attached to a 
fluorescence microscope Nikon Eclipse TS100 (Kurobane Nikon Co Ltd, Tochigi, Japan) at 4×. The length of the 
tubular network was measured using ImageJ 1.45 S software. We repeat this assay four times.
Western blotting. Cells were washed with PBS and proteins were collected using RIPA buffer, containing 1% 
protease inhibitor cocktail. The protein concentration was measured using the method of Lowry86 in the spectro-
photometer (Multiskan ex, Thermo Scientific) at a wavelength of 620 nm, using a standard curve of albumin. As 




























Table 1. Primers used for amplification of mRNA transcripts.
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in previous works87, cellular proteins were separated by SDS-PAGE and transferred to a polyvinylidene fluoride 
(PVDF) membrane (Bio-Rad) from the polyacrylamide gel. Then, the membranes were blocked by incubation 
(1 hour at room temperature) in TBS-T buffer (10 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.05% Tween 20) with 
3% bovine serum albumin (BSA). Later the membranes were incubated with the primary antibody, first for 1 h at 
room temperature and then overnight at 4 °C and under stirring, and then incubated with the respective fluores-
cent secondary antibody for 30 minutes at room temperature. We used the following antibodies: rabbit anti-AKT 
antibody (Cell Signaling Technology, Danvers, MA, USA), rabbit anti-P-AKT antibody (Santa Cruz, CA, USA), 
mouse anti-ERK½ antibody (Santa Cruz, CA, USA), rabbit anti-P-ERK½ antibody (Cell Signaling Technology, 
Danvers, MA, USA), mouse anti-GAPDH antibody (Santa Cruz, CA, USA). Protein bands were detected by 
incubating with anti-rabbit IRDye- 680RD LI-COR Biotechnology, Lincoln, Nebraska, USA Red (700 nm) or 
anti-mouse IRDye-800CW LI-COR Biotechnology, Lincoln, Nebraska, USA Green (800 nm). Fluorescence was 
detected using the LI-COR Odyssey IR Imaging System V3.0 system (LI-COR Odyssey Biosciences). The optical 
density of the bands was determined with the ImageJ program.
Vascular permeability assay. Endothelial permeability was determined by diffusing of 40 kDa fluorescein 
isothiocyanate (FITC)-dextran through the endothelial cells88. As in previous works87, endothelial cells, control 
and melatonin treated for a week, were grown to confluence on collagen-coated inserts. In order to stimulate 
endothelial cell permeability VEGF 4 ng/ml was added to the plates and inserts and docetaxel 10 nM, vinorelbine 
10 nM and/or melatonin 1 mM were added. After 24 h, FITC-dextran solution was added to the cultures. The 
fluorescence intensity of FITC-dextran that crossed the endothelial monolayer at 30, 60 and 90 min was measured 
by using a microplate reader at 485/530 nm (Labsystems Multiskan RC 351, Vienna, VA, USA).
Immunofluorescence assay. Immunolabeling was analyzed in control or melatonin treated HUVECs 
grown on coverslips as described previously87. Cells were treated with docetaxel 10 nM, vinorelbine 10 nM and/or 
melatonin 1 mM. After 24 h, cells were fixed in 100% methanol (5 min) at room temperature. Then, after washing 
carefully, crystals were placed in a Petri dish and cells were permeabilized with PBS with 10% goat serum, 0.3 M 
glycine, 1% BSA and 0.1% tween for 1 h at room temperature. Primary antibody staining was performed for rab-
bit policlonal anti-VE-cadherin (ab33168) (Abcam, Cambridge, UK) at 1 µg/ml. After several PBS washes, cells 
were incubated for 1 h at room temperature with the secondary antibody conjugated with a fluorochrome, FITC 
(Jackson ImmunoResearch Laboratories, Inc., USA). Then, crystals were washed with 1x PBS, dried thoroughly 
and a drop of vectashield mounting medium (Vector Laboratories, Peterborough, UK) was added. Observation 
was made with a LSM51O laser confocal microscope (Zeiss).
Chick chorioallantoic membrane model of angiogenesis. As an in vivo model for studying angiogen-
esis we used the chick chorioallantoic membrane (CAM) model assay as described elsewhere88. All experiments 
were approved by the Bioethics Committee of the University of Cantabria and carried out in full accordance with 
the guidelines of the European Community (2010/63/EU) and the Spanish regulations (RD 53/2013). Fertilized 
eggs were incubated at 37 °C in a humidified incubator for 3 days. To allow detachment of the developing CAM 
shell we removed 4 ml of egg albumin with a hypodermic needle. At day 4, the shells were covered with a trans-
parent adhesive tape and a small window sawed with scissors on the broad side directly over the avascular portion 
of the embryonic membrane. At day 11, alginate beads containing PBS, VEGF, docetaxel 1 μM, vinorelbine 1 μM 
and/or melatonin 1 mM per bead were grafted on the CAM. VEGF 1.57 pM was used as a positive control of angi-
ogenic compound whereas PBS was used as a negative control. Chemical agents were dissolved in 1% dimethyl 
sulfoxide. After 72 h new blood vessels converging towards the implant were counted at 5 x magnification under 
a STEMI SR stereomicroscope equipped with a 100 mm objective with adapter ring 47070 (Zeiss) and fixed with 
7% buffered formalin and photographed.
Statistical analysis. Using GraphPad Prism software, statistical differences between groups were analyzed 
by one way analysis of variance (ANOVA), followed by the Student-Newman-Keuls test. Results were considered 
as statistically significant at p < 0.05. The data are showed as the mean ± standard errors of the mean (S.E.M.).
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